DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW

Objective: The evidence guiding VTE management in SCD, specifically in terms of anticoagulant choice, is scarce. Therefore, we conducted a systematic review that evaluates the effectiveness and safety of direct oral anticoagulants (DOACs) in SCD with VTE. Methodology: We performed a systematic revie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Waail Rozi, Abdulrahman Al-Mashdali, Elrazi Ali, Alaa Rahhal, Yousef Hailan, Mohamed Yassin
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/5713f6c64ea841169561944e81c21a13
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5713f6c64ea841169561944e81c21a13
record_format	dspace
spelling	oai:doaj.org-article:5713f6c64ea841169561944e81c21a132021-11-10T04:32:49ZDIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW2531-137910.1016/j.htct.2021.10.977https://doaj.org/article/5713f6c64ea841169561944e81c21a132021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S253113792101124Xhttps://doaj.org/toc/2531-1379Objective: The evidence guiding VTE management in SCD, specifically in terms of anticoagulant choice, is scarce. Therefore, we conducted a systematic review that evaluates the effectiveness and safety of direct oral anticoagulants (DOACs) in SCD with VTE. Methodology: We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the English literature (PubMed, SCOPUS, and Google Scholar) for randomized controlled trials, observational studies, reviews, case series, and case reports for patients with SCD treated with DOAC for thromboembolic disease. Results: The current data demonstrated that the use of DOACs for VTE in SCD has similar effectiveness in the prevention of VTE recurrence in comparison to other anticoagulants, including VKAs and injectable anticoagulants with a better safety profile. However, given the absence of clinical practice guidelines for the treatment of VTE among patients with SCD, the clinical practice guidelines recommendations for VTE treatment can be applied to patients with SCD. Conclusion: In view of the current evidence and based on the results observed; using DOACs was associated with lesser bleeding incidence and fewer complications comparing to VKAs. We think it is rational to use DOACs for VTE treatment among patients with SCD rather than use VKAs.Waail RoziAbdulrahman Al-MashdaliElrazi AliAlaa RahhalYousef HailanMohamed YassinElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S19- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Waail Rozi Abdulrahman Al-Mashdali Elrazi Ali Alaa Rahhal Yousef Hailan Mohamed Yassin DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW
description	Objective: The evidence guiding VTE management in SCD, specifically in terms of anticoagulant choice, is scarce. Therefore, we conducted a systematic review that evaluates the effectiveness and safety of direct oral anticoagulants (DOACs) in SCD with VTE. Methodology: We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the English literature (PubMed, SCOPUS, and Google Scholar) for randomized controlled trials, observational studies, reviews, case series, and case reports for patients with SCD treated with DOAC for thromboembolic disease. Results: The current data demonstrated that the use of DOACs for VTE in SCD has similar effectiveness in the prevention of VTE recurrence in comparison to other anticoagulants, including VKAs and injectable anticoagulants with a better safety profile. However, given the absence of clinical practice guidelines for the treatment of VTE among patients with SCD, the clinical practice guidelines recommendations for VTE treatment can be applied to patients with SCD. Conclusion: In view of the current evidence and based on the results observed; using DOACs was associated with lesser bleeding incidence and fewer complications comparing to VKAs. We think it is rational to use DOACs for VTE treatment among patients with SCD rather than use VKAs.
format	article
author	Waail Rozi Abdulrahman Al-Mashdali Elrazi Ali Alaa Rahhal Yousef Hailan Mohamed Yassin
author_facet	Waail Rozi Abdulrahman Al-Mashdali Elrazi Ali Alaa Rahhal Yousef Hailan Mohamed Yassin
author_sort	Waail Rozi
title	DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW
title_short	DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW
title_full	DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW
title_fullStr	DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW
title_full_unstemmed	DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW
title_sort	direct oral anticoagulants in sickle cell disease, where we stand and where we are heading: a systematic review
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/5713f6c64ea841169561944e81c21a13
work_keys_str_mv	AT waailrozi directoralanticoagulantsinsicklecelldiseasewherewestandandwhereweareheadingasystematicreview AT abdulrahmanalmashdali directoralanticoagulantsinsicklecelldiseasewherewestandandwhereweareheadingasystematicreview AT elraziali directoralanticoagulantsinsicklecelldiseasewherewestandandwhereweareheadingasystematicreview AT alaarahhal directoralanticoagulantsinsicklecelldiseasewherewestandandwhereweareheadingasystematicreview AT yousefhailan directoralanticoagulantsinsicklecelldiseasewherewestandandwhereweareheadingasystematicreview AT mohamedyassin directoralanticoagulantsinsicklecelldiseasewherewestandandwhereweareheadingasystematicreview
_version_	1718440649551773696

DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW

Ejemplares similares